Morepen Laboratories Ltd
MOREPENLABMorepen Laboratories Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the P/E sits at the 77th percentile of its own range — the multiple has already done part of the work.
The price is in a confirmed uptrend (3 weeks in) while the P/E sits at the 77th percentile of its own 10-year range. Underneath, the last four quarters read deteriorating — profit −20.0% year on year, and 44% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Morepen Laboratories Ltd trades at ₹58.9, in a confirmed uptrend and 3 weeks into that stage. That is +23.9% against its own 200-day average. It sits at 87% of a 52-week range of ₹34 to ₹63. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 10 straight weeks.
Today the stock is in a confirmed uptrend — week 3 of stage 2, confirmed. At ₹58.9 it trades +23.9% versus its 200-day average and sits at 87% of its 52-week range (₹34–₹63).
Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +118% while the NIFTY 500 moved +274% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 10 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 77th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Morepen Laboratories Ltd trades at 39.6× P/E, at the pricey end of its own range (77th percentile). Its long-run median P/E is 30.2×, measured across 9.9 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 39.6× is at the pricey end of its own range (77th percentile), against a long-run median of 30.2× measured over 9.9 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −19.5% against a −5.8% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the −2.5%/yr price move, ~−8.8%/yr came from earnings growth and ~+6.3 pp from the multiple (expanding); over 10y, of the +9.4%/yr price move, ~+13.6%/yr came from earnings growth and ~−4.2 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Morepen Laboratories Ltd reads as deteriorating on its fundamental arc. Deteriorating — revenue, profit and EPS growth are shrinking (revenue growth −0.3% latest against +19.2% at its 12-quarter best), ROCE holding at 10.0%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −0.3% | +8.4% | +8.7% | +14.1% |
| Profit | −18.6% | +35.0% | −0.2% | +22.1% |
| EPS | −19.5% | +31.5% | −4.3% | +20.0% |
| Share price | −5.8% | +26.0% | −2.5% | +9.4% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
36.3/100 — rank 19 of 24 in Pharma - API & CRAMS · 90% evidence confidence
Morepen Laboratories Ltd scores 36.3 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 19. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 8.8 + 9.3 + 9.5 + 8.7 = 36.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Morepen Laboratories Ltd reported ₹485 Cr of revenue in the Mar 26 quarter, +4.1% year on year. That is the 2nd straight quarter of year-on-year growth. Over 10 years it has compounded at 14.1% a year. The last full year, FY26, came in at ₹1,806 Cr. The last four reported quarters add to ₹1,806 Cr.
Morepen Laboratories Ltd reported ₹485 Cr of revenue in the Mar 26 quarter, +4.1% year on year. That is the 2nd straight quarter of year-on-year growth. Over 10 years it has compounded at 14.1% a year. The last full year, FY26, came in at ₹1,806 Cr. The last four reported quarters add to ₹1,806 Cr.
FY26 revenue came in at ₹1,806 Cr (−0.3% on the year), capping 10 years at 14.1% compound. The latest quarter (Mar 26) printed ₹485 Cr, +4.1% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged −0.4% growth against the decade's 14.1% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −0.3% over the last 4 quarters against +3.3%/yr over the last 8 — rolling over; TTM profit −18.6% vs −0.5%/yr — rolling over.
→ Revenue grew — did margins hold as it scaled? Next: 5.0% this quarter (−4.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Morepen Laboratories Ltd's operating margin is 5.0% in the Mar 26 quarter, −4.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 6.0% to 13.0%. The current quarter is running below every full year in that window.
Morepen Laboratories Ltd's operating margin is 5.0% in the Mar 26 quarter, −4.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 6.0% to 13.0%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 5.0%, −4.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 6.0%–13.0%.
🚨 Why the margin moved: operating margin went −4.0 pp year on year while gross margin went +6.1 pp — the loss came mostly from the gross line: input costs and pricing.
→ Margins slipped — did that reach the bottom line? Next: profit −20.0% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Morepen Laboratories Ltd earned ₹16.0 Cr of net profit in the Mar 26 quarter, −20.0% year on year. Full-year FY26 profit was ₹96.0 Cr. The 10-year compound rate is 22.1%. That is 3.3% of the quarter's revenue. The same quarter a year earlier earned ₹20.0 Cr.
Morepen Laboratories Ltd earned ₹16.0 Cr of net profit in the Mar 26 quarter, −20.0% year on year. Full-year FY26 profit was ₹96.0 Cr. The 10-year compound rate is 22.1%. That is 3.3% of the quarter's revenue. The same quarter a year earlier earned ₹20.0 Cr.
Mar 26 profit was ₹16.0 Cr, −20.0% year on year. On the full year, FY26 printed ₹96.0 Cr (−18.6%), and the 10-year compound rate is 22.1%.
🚨 Why profit moved: revenue contributed +4.1% and the margin −4.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −17.1% vs revenue −0.4%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
→ Profit rose — but did the cash follow? Next: 44% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 44% of Morepen Laboratories Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹33.0 Cr of operating cash against ₹96.0 Cr of profit. After ₹54.0 Cr of capital spending, ₹−21.0 Cr was left as free cash.
FY26: operating cash of ₹33.0 Cr against reported profit of ₹96.0 Cr, leaving free cash of ₹−21.0 Cr after ₹54.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 44% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 44%: the cash cycle stretched 13 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 13 days — the next section's job is to find where the cash is stuck.
→ So follow the cash to where it goes. Next: the 53-day cycle, in money terms.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Morepen Laboratories Ltd's cash conversion cycle runs 53 days in FY26, up from 40 days in FY21. Capital spending ran ₹349 Cr over the last 3 years. At FY26 sales of ₹1,806 Cr each day of that cycle holds about ₹4.9 Cr, so roughly ₹262 Cr sits inside the business at any moment.
FY26: debtors at 67 days, inventory at 88 days — roughly 2.9 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 53 days, looser than FY21's 40.
The full loop: cash goes out to suppliers and production on day 0; stock waits 88 days to sell; customers pay about 67 days after that; and suppliers themselves are paid at 103 days — netting out to the 53-day cycle.
In money terms: at FY26 sales of ₹1,806 Cr, each day of the cycle holds about ₹4.9 Cr — so the 53-day loop keeps roughly ₹262 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹349 Cr over the last 3 fiscal years against ₹98.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹22.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 8% and the ROIC − WACC spread is −6.6 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Morepen Laboratories Ltd earns a ROCE of 8% in FY26. That is up from a trough of 1% in FY14. Return on invested capital clears the cost of that capital by −6.6 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 5.3% net margin on 0.93× asset turns.
FY26 ROCE is 8%, recovered from a FY14 trough of 1% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 5.3% net margin × 0.93× asset turns × 1.55× balance-sheet leverage ≈ 7.6% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 5.4% − 12.0% = a −6.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.17.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Morepen Laboratories Ltd carries total debt of ₹208 Cr against shareholder equity of ₹1,247 Cr as of Mar 26, a debt-to-equity of 0.17 — effectively unlevered. On the annual view that ratio went from 0.23 in FY22 to 0.17 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹208 Cr against shareholder equity of ₹1,247 Cr — a debt-to-equity of 0.17. On the annual view, debt-to-equity went from 0.23 (FY22) to 0.17 (FY26). The returns on this page are earned, not borrowed.
→ Who owns this, and are they adding or leaving? Next: Promoters cut 2.6 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 2.6 points of Morepen Laboratories Ltd over 8 quarters, the biggest move on the register. That takes promoters to 35.7% of the company. Domestic institutions moved −0.9 points over the same window, to 1.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: −2.6 points over 8 quarters to 35.7%; Domestic institutions: −0.9 points over 8 quarters to 1.3%; Foreign institutions: −0.2 points over 8 quarters to 1.5%.
🚨 Why the register moved: promoters drove it (−2.6 points), alongside domestic institutions (−0.9 points) — distribution into the market’s bid.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Morepen Laboratories Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Morepen Laboratories Ltd this page | 39.6× | ₹2,948 Cr | Mixed | |||
| Divis Laboratories Ltd | 73.4× | ₹1.9L Cr | Mixed | |||
| Laurus Labs Ltd | 79.1× | ₹86,505 Cr | Mixed | |||
| Anthem Biosciences Ltd | 73.1× | ₹43,360 Cr | No read | |||
| Gland Pharma Ltd | 37.6× | ₹39,257 Cr | Improving | |||
| Acutaas Chemicals Ltd | 75.2× | ₹26,785 Cr | Improving | |||
| Acutaas Chemicals Ltd | 69.1× | ₹26,686 Cr | Mixed | |||
| Sai Life Sciences Ltd | 73.8× | ₹26,174 Cr | No read | |||
| Piramal Pharma Ltd | — | ₹24,133 Cr | No read | |||
| Neuland Laboratories Ltd | 65.9× | ₹23,794 Cr | Turning around | |||
| Granules India Ltd | 31.8× | ₹20,655 Cr | Consistent | |||
| OneSource Specialty Pharma Ltd | — | ₹18,961 Cr | No read | |||
| Syngene International Ltd | 44.9× | ₹16,708 Cr | Turning around | |||
| Syngene International Ltd | 44.1× | ₹16,415 Cr | Turning around | |||
| Cohance Lifesciences Ltd | 80.9× | ₹15,957 Cr | Deteriorating | |||
| Jubilant Pharmova Ltd | 35.2× | ₹15,378 Cr | No read | |||
| Concord Biotech Ltd | 54.8× | ₹13,061 Cr | Deteriorating | |||
| Shilpa Medicare Ltd | 50.8× | ₹11,856 Cr | No read | |||
| Blue Jet Healthcare Ltd | 43.3× | ₹10,730 Cr | Deteriorating | |||
| Supriya Lifescience Ltd | 32.3× | ₹6,765 Cr | Consistent | |||
| IOL Chemicals & Pharmaceuticals Ltd | 30.0× | ₹4,380 Cr | Improving | |||
| SMS Pharmaceuticals Ltd | 35.0× | ₹3,569 Cr | Mixed | |||
| Dishman Carbogen Amcis Ltd | 29.0× | ₹2,878 Cr | No read | |||
| Hikal Ltd | 73.8× | ₹2,681 Cr | Deteriorating | |||
| Solara Active Pharma Sciences Ltd | 551.0× | ₹2,351 Cr | No read | |||
| Windlas Biotech Ltd | 26.6× | ₹1,770 Cr | Mixed |
Frequently asked questions
What is Morepen Laboratories Ltd's share price today?
Morepen Laboratories Ltd trades at ₹58.9, −5.8% over the past year. The company is valued at ₹2,948 Cr. The stock sits at 87% of its 52-week range of ₹34–₹63, +23.9% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 3 weeks in. — as of 24 July 2026.
What were Morepen Laboratories Ltd's latest quarterly results?
Morepen Laboratories Ltd reported revenue of ₹485 Cr and net profit of ₹16.0 Cr for the Mar 26 quarter. Revenue rose 4.1% and profit fell 20.0% year on year. Earnings per share were ₹0.29. The operating margin was 5.0%, 4.0 pp lower than a year earlier. — as of 24 July 2026.
What is Morepen Laboratories Ltd's revenue?
Morepen Laboratories Ltd reported revenue of ₹485 Cr in the Mar 26 quarter, +4.1% year on year. For the full FY26 fiscal year, revenue was ₹1,806 Cr (−0.3%). Over the last 10 years revenue compounded at 14.1% a year. — as of 24 July 2026.
What is Morepen Laboratories Ltd's profit?
Morepen Laboratories Ltd earned ₹16.0 Cr of net profit in the Mar 26 quarter, −20.0% year on year. Full-year FY26 profit was ₹96.0 Cr. The operating margin ran 5.0% in the latest quarter. — as of 24 July 2026.
What is Morepen Laboratories Ltd's market cap?
Morepen Laboratories Ltd's market capitalisation is ₹2,948 Cr at a share price of ₹58.9. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Morepen Laboratories Ltd's P/E ratio?
Morepen Laboratories Ltd trades at a P/E of 39.6×, at the 77th percentile of its own 10-year range, against a long-run median of 30.2×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Morepen Laboratories Ltd pay a dividend?
Yes — Morepen Laboratories Ltd's dividend payout was 12% of profit in FY26, and it recorded a payout in 2 of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Morepen Laboratories Ltd overvalued?
On its own history, Morepen Laboratories Ltd looks expensive against its own history: its P/E of 39.6× sits at the 77th percentile of its 10-year range (long-run median 30.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Morepen Laboratories Ltd growing?
Not right now — Morepen Laboratories Ltd's latest numbers are shrinking: latest-quarter revenue +4.1% year on year, profit −20.0%, and the margin −4.0 pp at 5.0%. The 10-year compound rates are 14.1% (revenue) and 22.1% (profit). The earnings engine currently reads: deteriorating — as of 24 July 2026.
How is Morepen Laboratories Ltd performing?
Morepen Laboratories Ltd is in a confirmed uptrend, 3 weeks in. Its latest quarter's revenue rose 4.1% and profit fell 20.0% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 10 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Morepen Laboratories Ltd in?
Deteriorating — revenue, profit and EPS growth are shrinking (revenue growth −0.3% latest against +19.2% at its 12-quarter best), ROCE holding at 10.0%. The read comes from the last 12 quarters of growth (revenue growth −0.3% latest, profit growth −18.6% latest, eps growth −21.3% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Morepen Laboratories Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 3 of stage 2), trading +23.9% versus its 200-day average and at 87% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Morepen Laboratories Ltd beating the market?
On recent form, yes — Morepen Laboratories Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 10 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.3 years the stock moved +118% against the NIFTY 500's +274% — behind the index over the full window. — as of 24 July 2026.
Will Morepen Laboratories Ltd's share price go up?
This page publishes no price forecast for Morepen Laboratories Ltd. What it measures instead: the share price is ₹58.9, the price is in a confirmed uptrend 3 weeks in. Its P/E of 39.6× sits at the 77th percentile of its own 10-year range. — as of 24 July 2026.
Who owns Morepen Laboratories Ltd?
Promoters hold 35.7% of Morepen Laboratories Ltd, foreign institutions 1.5%, domestic institutions 1.3% and the public 61.6% (latest quarter). The biggest move on the register over the last two years: Promoters cut 2.6 points over 8 quarters. — as of 24 July 2026.
Does Morepen Laboratories Ltd have too much debt?
No — Morepen Laboratories Ltd's debt-to-equity is 0.17, and operating profit covers the interest bill 8×. FY26 borrowings were ₹208 Cr against equity of ₹1,247 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Morepen Laboratories Ltd's capex?
Morepen Laboratories Ltd spent ₹349 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹54.0 Cr, with ₹22.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Morepen Laboratories Ltd's cash flow?
Morepen Laboratories Ltd generated ₹33.0 Cr of operating cash flow in FY26 and ₹−21.0 Cr of free cash flow after ₹54.0 Cr of capital spending. Reported profit that year was ₹96.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Morepen Laboratories Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 44% of Morepen Laboratories Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹33.0 Cr against reported profit of ₹96.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 24 July 2026.
Where is Morepen Laboratories Ltd in its business cycle?
Morepen Laboratories Ltd's FY26 operating margin was 7.0%, against a 13-year band of 6.0%–13.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 5.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Morepen Laboratories Ltd story?
Biggest watch item: the P/E sits at the 77th percentile of its own range — the multiple has already done part of the work. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Morepen Laboratories Ltd a stock worth studying right now?
This is not investment advice. The machine read: Morepen Laboratories Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.